Skip to main content
Premium Trial:

Request an Annual Quote

Schering Will Utilize Myriad's ProNet Product


SALT LAKE CITY--In a collaboration that Myriad Genetics here values at $51 million, German pharmaceutical company Schering will use Myriad's protein-to-protein interaction technology ProNet to study biochemical pathways of major diseases. In North America, Myriad will have an option to copromote in all new therapeutic products and receive 50 percent of profits from sales of drugs discovered using the technology. Myriad said it will collaborate with Schering scientists to identify drug targets using ProNet to reveal the cascade of protein interactions that lead to major human diseases.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.